- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
- 10-Q Quarterly report
- 10.2 Stock Option Grant Notice and Agreement
- 10.3 ZIVO Bioscience, Inc. Nonemployee Director Compensation Policy
- 31.1 Certification Pursuant to Rule 13A-14(A)/15D-14(A) Certifications Section 302 of the Sarbanes-oxly Act of 2002
- 31.2 Certification Pursuant to Rule 13A-14(A)/15D-14(A) Certifications Section 302 of the Sarbanes-oxly Act of 2002
- 32.1 Certificate Pursuant to Section 18 U.s.c. Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- 32.2 Certificate Pursuant to Section 18 U.s.c. Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- Download Excel data file
- View Excel data file
EXHIBIT 32.2
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
In connection with the Quarterly Report of Zivo Bioscience, Inc., a Nevada corporation (the “Company”), on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Keith Marchiando, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to the best of my knowledge and belief:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and |
|
|
|
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Keith Marchiando | |
| Keith Marchiando | |
| Chief Financial Officer | |
|
|
| Dated: November 15, 2021 |